SEC Form 4 · accession 0001209191-16-140853
Lineage Cell Therapeutics, Inc. · LCTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Russell Skibsted
Officer — Chief Financial Officer
Period of report
Sep 8, 2016
Accepted (ET)
Sep 9, 2016 · 9:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000876343
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common SharesF1 | $3.49 | Sep 8, 2016 | A | 50,000 | A | — | Sep 7, 2026 | Common Shares | 50,000 | 50,000 | D |
| Option to Purchase Common SharesF2 | $3.36 | holding | — | — | — | — | Nov 15, 2025 | Common Shares | 450,000 | 450,000 | D |
Explanation of responses
- F1One quarter of the options shall vest upon the completion of 12 months of continuous employment from the date of grant on September 8, 2016 and the balance shall vest in 36 monthly installments upon the completion of each month of continuous employment from the first anniversary of the date of grant.
- F2One quarter of the options shall vest upon the completion of 12 months of continuous employment from the date of grant on November 16, 2015 and the balance shall vest in 36 monthly installments upon the completion of each month of continuous employment from the first anniversary of the date of grant.